Six-month open-label study showed clinically meaningful improvements in kidney function and disease in patients with Type 2 diabetic nephropathy. 71% achieved a >30% reduction in UP/Cr, a key ...

THURSDAY, April 10, 2025 (HealthDay News) -- Among U.S. adults without diabetes, the use of glucagon-like peptide 1 receptor agonists (GLP-1 RAs) increased from 2018 to 2022, reaching annual ...

36% had reduced urinary synaptopodin losses, indicating healthier kidney cells and structure. "The positive results from our Phase 2b study evaluating a melanocortin agonist in patients with diabetic ...

Lundbeck’s receptor superagonist designed to treat seizures associated with developmental and epileptic encephalopathies (DEEs) has seen a 61.2% reduction in total seizures in a Phase Ib/IIa trial.

The trial has seen the therapy able to elicit a 57.3% reduction in countable motor seizures and 61.2% reduction in total seizures. Credit: Shutterstock / Tunatura Lundbeck’s receptor superagonist ...

About KGF alternative peptide (FGFR2b agonist) [Product code: PG-012] Mechanism of activating FGFR2b by the KGF alternative peptide (PG-012) PG-012, KGF alternative peptide, is a dimeric peptide ...

(Headquarters: Chiyoda-ku, Tokyo, President: Junichiro Ishizuka) has successfully developed a novel synthetic peptide called "KGF alternative- peptide (FGFR2b agonist)" which is functionally ...

The data also showed that low dose MC4R agonist bremelanotide stopped the rapid weight regain seen after ending GLP-1/GIP tirzepatide treatment." Topline data results from the study were highly ...

Primary endpoint met in the 8-week treatment study (highly statistically significant).Co-administered group had a 4.4% reduction in weight compared to 1.6% for the placebo group (p<0.0001).Primary ...